Stock DNA
Pharmaceuticals & Biotechnology
JPY 96,161 Million (Small Cap)
31.00
NA
0.02%
-0.04
6.20%
2.30
Revenue and Profits:
Net Sales:
10,197 Million
(Quarterly Results - Jun 2025)
Net Profit:
600 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.34%
0%
-1.34%
6 Months
19.16%
0%
19.16%
1 Year
10.28%
0%
10.28%
2 Years
40.34%
0%
40.34%
3 Years
30.94%
0%
30.94%
4 Years
23.98%
0%
23.98%
5 Years
23.1%
0%
23.1%
Eiken Chemical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.07%
EBIT Growth (5y)
-8.29%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.82
Tax Ratio
25.51%
Dividend Payout Ratio
81.76%
Pledged Shares
0
Institutional Holding
0.35%
ROCE (avg)
17.07%
ROE (avg)
9.70%
Valuation key factors
Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
1.78
EV to EBIT
23.70
EV to EBITDA
12.80
EV to Capital Employed
1.91
EV to Sales
1.75
PEG Ratio
NA
Dividend Yield
0.03%
ROCE (Latest)
8.07%
ROE (Latest)
5.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.35%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
10,197.00
9,899.00
3.01%
Operating Profit (PBDIT) excl Other Income
1,349.00
1,060.00
27.26%
Interest
4.00
5.00
-20.00%
Exceptional Items
0.00
-250.00
100.00%
Consolidate Net Profit
600.00
112.00
435.71%
Operating Profit Margin (Excl OI)
78.60%
36.80%
4.18%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 3.01% vs -9.28% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 435.71% vs -86.12% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
40,539.00
40,052.00
1.22%
Operating Profit (PBDIT) excl Other Income
5,554.00
5,705.00
-2.65%
Interest
17.00
17.00
Exceptional Items
-250.00
0.00
Consolidate Net Profit
2,228.00
2,634.00
-15.41%
Operating Profit Margin (Excl OI)
74.00%
84.40%
-1.04%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 1.22% vs -7.44% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -15.41% vs -54.08% in Mar 2024
About Eiken Chemical Co., Ltd. 
Eiken Chemical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






